{"id":3672,"date":"2026-10-08T09:00:00","date_gmt":"2026-10-08T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3672"},"modified":"2026-10-08T19:55:29","modified_gmt":"2026-10-08T23:55:29","slug":"fda-hold-persists-as-evenamide-death-imbalance-is-disclosed","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3672","title":{"rendered":"FDA Hold Persists as Evenamide Death Imbalance Is Disclosed"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Newron Pharmaceuticals<\/p>\n

Event Type<\/strong><\/p>\n

FDA clinical hold rationale and safety disclosure<\/p>\n

Modality<\/strong><\/p>\n

Small molecule (selective voltage-gated sodium-channel blocker)<\/p>\n

Asset<\/strong><\/p>\n

Evenamide<\/p>\n

Target<\/strong><\/p>\n

Voltage-gated sodium channels (glutamate modulation)<\/p>\n

Disease Area<\/strong><\/p>\n

Treatment-resistant schizophrenia<\/p>\n

Summary<\/h4>\n

Newron disclosed the FDA\u2019s written rationale for maintaining the U.S. clinical hold on ENIGMA-TRS 2. The agency noted four deaths among evenamide-treated participants across the development program versus one among placebo participants and identified a potential class-linked arrhythmic mechanism that cannot be excluded retrospectively. The company is reviewing the feedback, considering additional cardiac screening and monitoring, and continues enrollment outside the United States.<\/p>\n

This is a high-importance safety signal, but the available evidence does not establish causality. The pooled disclosure lacks causes of death, exposure windows, adjudication methods, baseline cardiovascular risk, concomitant medication profiles, and randomized denominators by study. Newron\u2019s exposure-adjusted mortality comparison moves in the opposite direction from the crude imbalance, underscoring why neither metric alone is dispositive.<\/p>\n

FDA\u2019s concern relates to the known potential for some sodium-channel blockers to trigger arrhythmias that can lead to serious cardiovascular events or seizures. Evenamide is a selective voltage-gated sodium-channel blocker developed as a glutamate modulator. Four deaths occurred among evenamide-treated participants versus one on placebo. Investigators considered three unrelated and one possibly related; FDA nevertheless characterized the aggregate as a potential safety signal because a fatal arrhythmic mechanism cannot be definitively excluded after the event.<\/p>\n

Newron reported a very small QTc shortening signal, more than 10,000 ECGs across approximately 700 exposed subjects, and no observed pattern of cardiac abnormalities or arrhythmias. It also reported crude mortality of 0.56% for evenamide versus 0.27% for placebo, but exposure-adjusted rates of 1.31 versus 1.81 deaths per 100 patient-years, respectively. ENIGMA-TRS 1 is expected to finish enrollment in mid-October with 12-week topline data in the first quarter of 2027. ENIGMA-TRS 2 continues outside the United States; no U.S. participant has been dosed in that study.<\/p>\n

Deep Analysis<\/h4>\n

The regulatory issue is not a conventional QT-prolongation problem with a familiar action threshold. FDA is focused on a plausible sodium-channel mechanism, latent susceptibility, and the limits of standard screening. QTc shortening is an imperfect surrogate for proarrhythmia, and a normal baseline ECG does not reliably exclude inherited or acquired sodium-channel vulnerability. That makes causality assessment dependent on case-level timing, rhythm evidence, autopsy findings, drug levels, comedications, electrolyte status, seizure history, and genomic or phenotypic predisposition.<\/p>\n

The crude and exposure-adjusted mortality comparisons answer different questions. The crude proportion is relevant to the number of affected participants, while patient-year rates account for unequal follow-up. Both are unstable with five total events and heterogeneous studies. Pooling across doses, populations, durations, and trial designs may increase detection sensitivity but reduce interpretability. A lower exposure-adjusted rate does not dismiss a mechanism-specific cluster, and a higher crude proportion does not prove drug causality.<\/p>\n

The strongest benign interpretation is that the imbalance is stochastic or reflects background mortality in a population with severe schizophrenia, polypharmacy, metabolic disease, and reduced life expectancy. Support includes investigator assessments, the absence of a reported ECG pattern, and the company\u2019s exposure-adjusted calculation. The strongest adverse interpretation is that a rare, susceptibility-dependent channel effect is invisible to routine ECG surveillance but can precipitate catastrophic events. Support is FDA\u2019s class-mechanism concern and the inability to exclude arrhythmia in the possibly related death.<\/p>\n

Operationally, continued ex-U.S. enrollment preserves the development timeline but creates cross-jurisdictional asymmetry. If mitigation requires specialized ECG, ambulatory monitoring, genetic screening, electrolyte control, or exclusion of common antipsychotic combinations, feasibility and generalizability may change even if the hold is lifted. The Q1 2027 efficacy readout therefore cannot be interpreted independently of the evolving safety package.<\/p>\n

Company and Product Background<\/h4>\n

Evenamide is an investigational selective voltage-gated sodium-channel blocker intended to reduce abnormal glutamate release without direct dopamine receptor blockade. Newron is developing it as add-on therapy for treatment-resistant schizophrenia, including in patients receiving second-generation antipsychotics or clozapine.<\/p>\n

ENIGMA-TRS 1 is a global, randomized, placebo-controlled 52-week study with a 12-week primary PANSS assessment and at least 600 planned participants. ENIGMA-TRS 2 is a separate randomized, placebo-controlled 12-week study planned for at least 400 participants.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Verified facts: the U.S. hold remains; FDA cited four deaths on evenamide and one on placebo; one evenamide death was considered possibly related; no U.S. participant has been dosed in ENIGMA-TRS 2; non-U.S. enrollment continues.<\/li>\n
  • Company claims: no pattern of arrhythmia has been observed in preclinical or clinical data, including a thorough-QT study and extensive ECG monitoring. These data have not been independently presented in the disclosure.<\/li>\n
  • Interpretation A: a rare, mechanism-linked arrhythmic risk exists and current screening is insufficient. This would be upgraded by rhythm-documented events, temporal concentration around dosing, dose dependence, or reproducible channel effects. It would be weakened by independent adjudication establishing non-cardiac causes with no exposure relationship.<\/li>\n
  • Interpretation B: the imbalance is chance or confounding in a high-risk population. This would be upgraded by balanced randomized exposure, lower or comparable adjudicated event rates, and clean prospective monitoring. It would be weakened by additional unexplained syncope, seizure, ventricular arrhythmia, or sudden death.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    The appropriate stance is negative on regulatory execution and uncertain on causality. The hold delays U.S. development and raises the evidence burden, regardless of whether evenamide caused any death. The decisive next step is not another aggregate reassurance; it is a regulator-acceptable prospective mitigation plan tied to transparent case-level adjudication.<\/p>\n

    An upgrade requires FDA acceptance of the response, predefined cardiac risk controls, resumption of U.S. enrollment, and no emerging event pattern. A downgrade would follow an expanded hold, protocol restrictions that materially impair recruitment or applicability, or new mechanistically coherent events.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 5 of 5. Signal Direction: negative for U.S. development; causality uncertain. Confidence in Facts: high. Confidence in Interpretation: low to moderate.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Newron disclosed the FDA\u2019s written rationale for maintaining the U.S. clinical hold on ENIGMA-TRS 2. The agency noted four deaths among evenamide-treated participants across the development program versus one among placebo participants and identified…<\/p>\n","protected":false},"author":1,"featured_media":3678,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[1006,1005,1008,1004,1009,1007],"class_list":["post-3672","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-enigma-trs","tag-evenamide","tag-fda-clinical-hold","tag-newron-pharmaceuticals","tag-sodium-channel-blocker","tag-treatment-resistant-schizophrenia"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3672","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3672"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3672\/revisions"}],"predecessor-version":[{"id":3683,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3672\/revisions\/3683"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3678"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3672"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3672"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3672"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}